Atherosclerosis

The article announces a correction to a previously published study on the AIM2 inflammasome's role in exacerbating atherosclerosis in clonal haematopoiesis, published in Nature on May 14, 2026. The study focuses on the relationship between the AIM2 inflammasome and atherosclerosis. The correction aims to rectify errors in the original publication.

Genome editing is highlighted as a risky technology, but a new approach called epigenome editing is introduced as a potential solution. The technology aims to address diseases such as atherosclerosis and hepatitis B.